BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006;106:1990-1997. [PMID: 16565970 DOI: 10.1002/cncr.21832] [Cited by in Crossref: 194] [Cited by in F6Publishing: 182] [Article Influence: 12.1] [Reference Citation Analysis]
Number Citing Articles
1 Ikeda M, Okusaka T, Furuse J, Mitsunaga S, Ueno H, Yamaura H, Inaba Y, Takeuchi Y, Satake M, Arai Y. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2013;72:463-470. [PMID: 23812005 DOI: 10.1007/s00280-013-2222-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
2 Yamasaki T, Saeki I, Sakaida I. Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments. Hepatol Int. 2014;8 Suppl 2:492-498. [PMID: 26201330 DOI: 10.1007/s12072-013-9515-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Kudo M. Management of Hepatocellular Carcinoma in Japan as a World-Leading Model. Liver Cancer 2018;7:134-47. [PMID: 29888204 DOI: 10.1159/000484619] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
4 Giorgio A, Calisti G, Montesarchio L, Scognamiglio U, Matteucci P, Coppola C, Scarano F, Amendola F, Giorgio V. Hepatocellular carcinoma invading portal venous system in cirrhosis: long term results of percutaneous radiofrequency ablation of both the nodule and portal vein tumor thrombus. A case control study. Anticancer Res. 2014;34:6785-6790. [PMID: 25368292 DOI: 10.2214/ajr.08.2087] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
5 Kitagawa K, Omoto C, Oda T, Araki A, Saito H, Shigemura K, Katayama T, Hotta H, Shirakawa T. Oral Combination Vaccine, Comprising Bifidobacterium Displaying Hepatitis C Virus Nonstructural Protein 3 and Interferon-α, Induces Strong Cellular Immunity Specific to Nonstructural Protein 3 in Mice. Viral Immunol 2017;30:196-203. [PMID: 28112593 DOI: 10.1089/vim.2016.0111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Ghavimi S, Apfel T, Azimi H, Persaud A, Pyrsopoulos NT. Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. J Clin Transl Hepatol. 2020;8:168-176. [PMID: 32832397 DOI: 10.14218/jcth.2020.00001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
7 Giorgio A, de Stefano G, Di Sarno A, Farella N, Giorgio V, Scognamiglio U, Mariniello A, Liorre G, Perrotta A, Mariniello N. Radiofrequency ablation of hepatocellular carcinoma extended into the portal vein: Preliminary results. J Ultrasound 2009;12:32-7. [PMID: 23396977 DOI: 10.1016/j.jus.2008.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
8 Lin CC, Hung CF, Chen WT, Lin SM. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer 2015;4:228-40. [PMID: 26734578 DOI: 10.1159/000367737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
9 Sanada Y, Yoshida K, Ohara M, Tsutani Y. Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res 2007;13:105-13. [DOI: 10.1007/bf02893485] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
10 Yamashita T. Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy. Clin Drug Investig 2012;32 Suppl 2:15-23. [PMID: 22873624 DOI: 10.1007/BF03265493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Miyahara K, Nouso K, Yamamoto K. Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol 2014; 20(15): 4151-4159 [PMID: 24764653 DOI: 10.3748/wjg.v20.i15.4151] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
12 Tomimaru Y, Eguchi H, Wada H, Noda T, Murakami M, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H. Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells. Br J Cancer 2010;102:1483-90. [PMID: 20407444 DOI: 10.1038/sj.bjc.6605669] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
13 Wada H, Nagano H, Yamamoto H, Noda T, Murakami M, Kobayashi S, Marubashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. BMC Cancer 2009;9:361. [PMID: 19821965 DOI: 10.1186/1471-2407-9-361] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
14 Moriguchi M, Takayama T, Higaki T, Kimura Y, Yamazaki S, Nakayama H, Ohkubo T, Aramaki O. Early cancer-related death after resection of hepatocellular carcinoma. Surgery. 2012;151:232-237. [PMID: 21176935 DOI: 10.1016/j.surg.2010.10.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
15 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
16 Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E; FAIT Research Group. 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study. Hepatol Res. 2012;42:150-165. [PMID: 22044786 DOI: 10.1111/j.1872-034x.2011.00905.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
17 Yamasaki T, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatol Res. 2012;42:340-348. [PMID: 22151009 DOI: 10.1111/j.1872-034x.2011.00938.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
18 Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2012;118:3302-3310. [PMID: 22072099 DOI: 10.1002/cncr.26648] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
19 Nagamatsu H, Sumie S, Niizeki T, Tajiri N, Iwamoto H, Aino H, Nakano M, Shimose S, Satani M, Okamura S. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemother Pharmacol. 2016;77:243-250. [PMID: 26754678 DOI: 10.1007/s00280-015-2892-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
20 Guo W, Chen S, Wu Z, Zhuang W, Yang J. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Technol Cancer Res Treat 2020;19:1533033820965587. [PMID: 33089769 DOI: 10.1177/1533033820965587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Yang JQ, Pan GD, Chu GP, Liu Z, Liu Q, Xiao Y, Yuan L. Interferon-alpha restrains growth and invasive potential of hepatocellular carcinoma induced by hepatitis B virus X protein. World J Gastroenterol 2008; 14(36): 5564-5569 [PMID: 18810776 DOI: 10.3748/wjg.14.5564] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
22 Ueshima K, Kudo M, Tanaka M, Kumada T, Chung H, Hagiwara S, Inoue T, Yada N, Kitai S. Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. Liver Cancer 2015;4:263-73. [PMID: 26734580 DOI: 10.1159/000367751] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
23 Wu J, Huang WJ, Wang HY, Wang YF, Peng BG, Zhou Q. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. Med Oncol 2015;32:65. [PMID: 25691293 DOI: 10.1007/s12032-015-0491-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Kawaoka T, Aikata H, Hyogo H, Morio R, Morio K, Hatooka M, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. J Dig Dis. 2015;16:505-512. [PMID: 26121102 DOI: 10.1111/1751-2980.12267] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
25 Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, Park SY, Yang JM. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50:445-454. [PMID: 25027973 DOI: 10.1007/s00535-014-0978-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
26 Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka AO. A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. Invest New Drugs 2014;32:762-8. [PMID: 24737402 DOI: 10.1007/s10637-014-0097-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Tateishi R, Shiina S, Ohki T, Sato T, Masuzaki R, Imamura J, Goto E, Goto T, Yoshida H, Obi S, Sato S, Kanai F, Yoshida H, Omata M. Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation. J Gastroenterol 2009;44:142-6. [DOI: 10.1007/s00535-008-2247-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
28 Masuzaki R, Yoshida H, Tateishi R, Shiina S, Omata M. Hepatocellular carcinoma in viral hepatitis: improving standard therapy. Best Pract Res Clin Gastroenterol. 2008;22:1137-1151. [PMID: 19187872 DOI: 10.1016/j.bpg.2008.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
29 Liang KH, Yang PC, Yeh CT. Genotyping the GALNT14 gene by joint analysis of two linked single nucleotide polymorphisms using liver tissues for clinical and geographical comparisons. Oncol Lett 2014;8:2215-20. [PMID: 25295111 DOI: 10.3892/ol.2014.2507] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
30 Oh MJ, Lee HJ, Lee SH. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. Clin Mol Hepatol. 2013;19:288-299. [PMID: 24133667 DOI: 10.3350/cmh.2013.19.3.288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
31 Kudo M, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y. Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer 2019;8:505-19. [PMID: 31799207 DOI: 10.1159/000503032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
32 Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer. 2010;103:1617-1626. [PMID: 20978511 DOI: 10.1038/sj.bjc.6605958] [Cited by in Crossref: 134] [Cited by in F6Publishing: 125] [Article Influence: 11.2] [Reference Citation Analysis]
33 Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, Chung YH, Lee YS, Lee SG, Park JH, Suh DJ. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys. 2012;82:2004-2011. [PMID: 21621346 DOI: 10.1016/j.ijrobp.2011.03.019] [Cited by in Crossref: 135] [Cited by in F6Publishing: 131] [Article Influence: 12.3] [Reference Citation Analysis]
34 Han KH, Park JY. Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. J Gastroenterol Hepatol 2010;25:1023-5. [PMID: 20594213 DOI: 10.1111/j.1440-1746.2010.06359.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
35 Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38:474-483. [PMID: 18430093 DOI: 10.1111/j.1872-034x.2008.00338.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
36 Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol. 2009;24:806-814. [PMID: 19207681 DOI: 10.1111/j.1440-1746.2008.05728.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 95] [Article Influence: 7.5] [Reference Citation Analysis]
37 Motegi S, Yokoo T, Nozawa R, Azumi R, Kawata Y, Ogawa K, Setsu T, Mizuno KI, Nishino K, Umezu H, Kawai H, Suda T, Terai S. Long-term survival of 11 years with multidisciplinary therapy for hepatocellular carcinoma metastasis to the ovary and peritoneum: a case report. Clin J Gastroenterol 2021;14:1211-20. [PMID: 33978943 DOI: 10.1007/s12328-021-01434-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Niizeki T, Iwamoto H, Shirono T, Shimose S, Nakano M, Okamura S, Noda Y, Kamachi N, Hiroyuki S, Sakai M, Kuromatsu R, Koga H, Torimura T. Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. Cancers (Basel) 2021;13:4450. [PMID: 34503259 DOI: 10.3390/cancers13174450] [Reference Citation Analysis]
39 Yuan Z, Wang Y, Hu C, Gao W, Zheng J, Li W. Efficacy of Percutaneous Thermal Ablation Combined With Transarterial Embolization for Recurrent Hepatocellular Carcinoma After Hepatectomy and a Prognostic Nomogram to Predict Survival. Technol Cancer Res Treat 2018;17:1533033818801362. [PMID: 30244651 DOI: 10.1177/1533033818801362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
40 Weber S, Jarnagin W, Duffy A, O'reilly EM, Abou-alfa GK, Blumgart L. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1569-94. [DOI: 10.1016/b978-0-443-06694-8.50088-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Inoue Y, Hasegawa K, Ishizawa T, Aoki T, Sano K, Beck Y, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma? Surgery. 2009;145:9-19. [PMID: 19081470 DOI: 10.1016/j.surg.2008.09.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
42 Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tsuboi K, Tokuuye K. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol. 2009;185:782-788. [PMID: 20013087 DOI: 10.1007/s00066-009-2020-x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 6.1] [Reference Citation Analysis]
43 Masaki T, Morishita A, Kurokohchi K, Kuriyama S. Multidisciplinary treatment of patients with hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;6:1377-84. [DOI: 10.1586/14737140.6.10.1377] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
44 Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Japanese Journal of Clinical Oncology 2018;48:103-14. [DOI: 10.1093/jjco/hyx180] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 15.6] [Reference Citation Analysis]
45 Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015; 7(12): 1632-1651 [PMID: 26140083 DOI: 10.4254/wjh.v7.i12.1632] [Cited by in Crossref: 120] [Cited by in F6Publishing: 107] [Article Influence: 17.1] [Reference Citation Analysis]
46 Ouyang G, Pan G, Xu H, Wu Y, Liu Z, Lu W, Yi B, Chen X. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2020;54:675-81. [PMID: 32569032 DOI: 10.1097/MCG.0000000000001384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Zhou C, Yu Q, Chen L, Wang J, Zheng S, Zhang J. A miR-1231 binding site polymorphism in the 3’UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility. Gene. 2012;507:95-98. [PMID: 22824466 DOI: 10.1016/j.gene.2012.06.073] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
48 Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, Bae SH, Choi JY, Yoon SK. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol 2017;9:615-26. [PMID: 28974984 DOI: 10.1177/1758834017728018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
49 Aoki T, Kubota K, Kubo S, Eguchi S, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Matsuyama Y, Murakami T, Kudo M. Analysis of Patient Outcome after Non-curative Resection for Hepatocellular Carcinoma Using Nationwide Survey Data in Japan. World J Surg 2021;45:607-14. [PMID: 33104834 DOI: 10.1007/s00268-020-05830-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Nagano H, Kobayashi S, Marubashi S, Wada H, Eguchi H, Tanemura M, Tomimaru Y, Umeshita K, Doki Y, Mori M. Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus. Exp Ther Med 2013;5:3-10. [PMID: 23251233 DOI: 10.3892/etm.2012.736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
51 Nagano H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Tomimaru Y, Osuga K, Umeshita K, Doki Y. Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology. 2011;80:63-69. [PMID: 21659784 DOI: 10.1159/000328281] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
52 Miyaki D, Aikata H, Kan H, Fujino H, Urabe A, Masaki K, Fukuhara T, Kobayashi T, Naeshiro N, Nakahara T. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. J Gastroenterol Hepatol. 2013;28:1834-1841. [PMID: 23808713 DOI: 10.1111/jgh.12311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
53 Zhuang BW, Li W, Xie XH, Hu HT, Lu MD, Xie XY. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. Jpn J Clin Oncol 2019;49:845-55. [PMID: 31063184 DOI: 10.1093/jjco/hyz069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
54 Zheng JS, Long J, Sun B, Lu NN, Fang D, Zhao LY, Du N. Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: extending the indication for ablation? Clin Radiol. 2014;69:e253-e263. [PMID: 24581962 DOI: 10.1016/j.crad.2014.01.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
55 Ikeda M, Okusaka T, Ueno H, Morizane C, Iwasa S, Hagihara A, Kojima Y. Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. Oncology 2007;72:188-93. [PMID: 18097170 DOI: 10.1159/000112805] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
56 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Evaluation of the "assessment for continuous treatment with hepatic arterial infusion chemotherapy" scoring system in patients with advanced hepatocellular carcinoma. Hepatol Res 2018;48:E87-97. [PMID: 28656680 DOI: 10.1111/hepr.12932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
57 Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, Kodama H, Shirakawa H, Kawakami Y, Takahashi S, Toyota N, Ito K, Chayama K. Similar effects of recombinant interferon-?-2b and natural interferon-? when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int 2007;0:070908015728003-???. [DOI: 10.1111/j.1478-3231.2007.01554.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
58 Azad A, Chionh F, Cebon J. Targeted agents for the systemic treatment of advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology 2009;5:76-86. [DOI: 10.1111/j.1743-7563.2009.01202.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
59 Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg Today. 2014;44:219-226. [PMID: 23591833 DOI: 10.1007/s00595-013-0585-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
60 Abdalla EK, Denys A, Hasegawa K, Leung TW, Makuuchi M, Murthy R, Ribero D, Zorzi D, Vauthey JN, Torzilli G. Treatment of large and advanced hepatocellular carcinoma. Ann Surg Oncol. 2008;15:979-985. [PMID: 18236115 DOI: 10.1245/s10434-007-9727-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
61 Hagiwara S, Kudo M, Nakatani T, Sakaguchi Y, Nagashima M, Fukuta N, Kimura M, Hayakawa S, Munakata H. Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53. Br J Cancer 2007;97:1532-7. [PMID: 17971768 DOI: 10.1038/sj.bjc.6604058] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
62 Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, Takahashi S, Toyota N, Ito K, Chayama K. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2007;42:845-853. [PMID: 17940838 DOI: 10.1007/s00535-007-2099-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
63 Zhang JB, Sun HC, Jia WD, Zhuang PY, Qian YB, Zhu XD, Kong LQ, Wang L, Wu WZ, Tang ZY. Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma. BMC Cancer 2012;12:439. [PMID: 23025904 DOI: 10.1186/1471-2407-12-439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
64 Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O. Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol 2015; 7(8): 1125-1132 [PMID: 26052401 DOI: 10.4254/wjh.v7.i8.1125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
65 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018; 10(9): 571-584 [PMID: 30310535 DOI: 10.4254/wjh.v10.i9.571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
66 Ohtsubo K, Watanabe H, Tsuchiyama T, Mouri H, Yamaguchi Y, Motoo Y, Okai T, Sanada J, Matsui O, Kitamura T, Fujiki R, Tokuuye K, Sawabu N. Advanced hepatocellular carcinoma treated effectively with irinotecan via hepatic arterial infusion followed by proton beam therapy. J Infect Chemother 2009;15:316-21. [PMID: 19856070 DOI: 10.1007/s10156-009-0702-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
67 Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Kenjo M, Toyota N, Ito K, Chayama K. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol. 2009;44:492-502. [PMID: 19330281 DOI: 10.1007/s00535-009-0033-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
68 Damdinsuren B, Nagano H, Monden M. Combined intra-arterial 5-fluorouracil and subcutaneous interferon-alpha therapy for highly advanced hepatocellular carcinoma. Hepatol Res 2007;37 Suppl 2:S238-50. [PMID: 17877489 DOI: 10.1111/j.1872-034X.2007.00191.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
69 Song DS, Bae SH, Song MJ, Lee SW, Kim HY, Lee YJ, Oh JS, Chun HJ, Lee HG, Choi JY, Yoon SK. Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2013; 19(29): 4679-4688 [PMID: 23922465 DOI: 10.3748/wjg.v19.i29.4679] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
70 Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Nakatani M, Kariya S, Yamaguchi T, Yoshida K, Yoshii K, Sekimoto M. The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion. Cancer Invest 2021;:1-9. [PMID: 34236269 DOI: 10.1080/07357907.2021.1952594] [Reference Citation Analysis]
71 Ishizaki M, Kaibori M, Matsui K, Ikeda H, Yoshida K, Okazaki K, Kariya S, Tanigawa N, Nakatake R, Matsushima H, Sakaguchi T, Kon M. Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma. Cancer Investigation 2017;35:271-6. [DOI: 10.1080/07357907.2017.1289382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Takaki-Hamabe S, Yamasaki T, Saeki I, Harima Y, Okita K, Terai S, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res. 2009;39:223-230. [PMID: 19054152 DOI: 10.1111/j.1872-034x.2008.00458.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
73 Saeki I, Yamasaki T, Tanabe N, Iwamoto T, Matsumoto T, Urata Y, Hidaka I, Ishikawa T, Takami T, Yamamoto N. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS One. 2015;10:e0126649. [PMID: 25992784 DOI: 10.1371/journal.pone.0126649] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
74 Nagamatsu H, Hiraki M, Mizukami N, Yoshida H, Iwamoto H, Sumie S, Torimura T, Sata M. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther. 2010;32:543-550. [PMID: 20500734 DOI: 10.1111/j.1365-2036.2010.04379.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
75 Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study. Mol Clin Oncol 2017;7:1013-20. [PMID: 29285366 DOI: 10.3892/mco.2017.1442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
76 Soroida Y, Ohkawa R, Nakagawa H, Satoh Y, Yoshida H, Kinoshita H, Tateishi R, Masuzaki R, Enooku K, Shiina S, Sato T, Obi S, Hoshino T, Nagatomo R, Okubo S, Yokota H, Koike K, Yatomi Y, Ikeda H. Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. Journal of Hepatology 2012;57:330-6. [DOI: 10.1016/j.jhep.2012.03.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
77 Mizumoto M, Oshiro Y, Okumura T, Fukumitsu N, Numajiri H, Ohnishi K, Aihara T, Ishikawa H, Tsuboi K, Sakurai H. Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience. Int J Part Ther 2016;2:570-8. [PMID: 31772968 DOI: 10.14338/IJPT-15-00035.2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Wada H, Nagano H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Sakon M, Wakasa K, Monden M. Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-α combination therapy following hepatic resection. J Gastroenterol 2007;42:501-6. [DOI: 10.1007/s00535-007-2028-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
79 Kasai K, Kuroda H, Ushio A, Sawara K, Takikawa Y, Suzuki K. Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion: preliminary results. Hepatol Res. 2009;39:117-125. [PMID: 19208032 DOI: 10.1111/j.1872-034x.2008.00414.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
80 Kosaka Y, Kawaoka T, Ogawa Y, Amioka K, Naruto K, Yoshikawa Y, Ando Y, Suehiro Y, Yamaoka K, Fujii Y, Uchikawa S, Ono A, Yamauchi M, Imamura M, Chosa K, Awai K, Nagata Y, Chayama K, Aikata H. Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study. Clin J Gastroenterol 2021. [PMID: 34291386 DOI: 10.1007/s12328-021-01481-9] [Reference Citation Analysis]
81 Lyu N, Kong Y, Pan T, Mu L, Li S, Liu Y, Deng H, Li J, Shi M, Xu L, Guo R, Chen M, Wu P, Zhao M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. J Vasc Interv Radiol 2019;30:349-357.e2. [PMID: 30819477 DOI: 10.1016/j.jvir.2018.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
82 Abou-alfa GK, Jarnagin W, Lowery M, D'angelica M, Brown K, Ludwig E, Covey A, Kemeny N, Goodman KA, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 1373-1396.e8. [DOI: 10.1016/b978-1-4557-2865-7.00080-1] [Reference Citation Analysis]
83 Yin XY, Jiang JM, Liu JY, Zhu JR. Effects of endogenous nitric oxide induced by 5-fluorouracil and L-Arg on liver carcinoma in nude mice. World J Gastroenterol 2007; 13(46): 6249-6253 [PMID: 18069768 DOI: 10.3748/wjg.v13.i46.6249] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
84 Miura T, Suzuki N, Nakamura J, Yamada S, Miura T, Yanagi M, Usuda H, Emura I, Takahashi T. Hepatocellular carcinoma, with portal thrombus after viral eradication, disappeared by 5-fluorouracil and interferon. World J Hepatol 2010; 2(11): 416-418 [PMID: 21173911 DOI: 10.4254/wjh.v2.i11.416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
85 Romano G, Kwong LN. Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. Cancer Metastasis Rev. 2018;37:45-53. [PMID: 29270700 DOI: 10.1007/s10555-017-9716-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
86 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy. PLoS One 2019;14:e0218136. [PMID: 31194789 DOI: 10.1371/journal.pone.0218136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
87 Yoon JH, Kim HC, Chung JW, Yoon JH, Jae HJ, Park JH. CT findings of completely regressed hepatocellular carcinoma with main portal vein tumor thrombosis after transcatheter arterial chemoembolization. Korean J Radiol 2010;11:69-74. [PMID: 20046497 DOI: 10.3348/kjr.2010.11.1.69] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
88 Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, Satake M, Arai Y, Okusaka T. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. J Gastroenterol 2014;49:932-40. [PMID: 23793266 DOI: 10.1007/s00535-013-0853-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
89 Ban D, Shimada K, Yamamoto Y, Nara S, Esaki M, Sakamoto Y, Kosuge T. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein. J Gastrointest Surg. 2009;13:1921-1928. [PMID: 19727969 DOI: 10.1007/s11605-009-0998-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
90 Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, Kondo S, Hagihara A, Shimizu S. Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Jpn J Clin Oncol. 2011;41:770-775. [PMID: 21459893 DOI: 10.1093/jjco/hyr037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
91 Chuma M, Uojima H, Hiraoka A, Kobayashi S, Toyoda H, Tada T, Hidaka H, Iwabuchi S, Numata K, Itobayashi E, Itokawa N, Kariyama K, Ohama H, Hattori N, Hirose S, Shibata H, Tani J, Imai M, Tajiri K, Moriya S, Wada N, Iwasaki S, Fukushima T, Ueno M, Yasuda S, Atsukawa M, Nouso K, Fukunishi S, Watanabe T, Ishikawa T, Nakamura S, Morimoto M, Kagawa T, Sakamoto M, Kumada T, Maeda S. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Hepatol Res. 2021;51:201-215. [PMID: 33270323 DOI: 10.1111/hepr.13592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
92 Tong J, Xie G, He J, Li J, Pan F, Liang H. Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol. 2011;2011:740564. [PMID: 21403907 DOI: 10.1155/2011/740564] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
93 Nishikawa H, Osaki Y, Kita R, Kimura T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Cancers (Basel) 2012;4:165-83. [PMID: 24213234 DOI: 10.3390/cancers4010165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
94 Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:123-133. [PMID: 22212946 DOI: 10.1159/000333275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
95 Gao XM, Zhu Y, Li JH, Wang XY, Zhang XF, Yi CH, Yang X. microRNA-26a induces a mitochondrial apoptosis mediated by p53 through targeting to inhibit Mcl1 in human hepatocellular carcinoma. Onco Targets Ther 2018;11:2227-39. [PMID: 29719405 DOI: 10.2147/OTT.S160895] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
96 Long J, Zheng J, Sun B, Lu N. Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study. Hepatol Int 2016;10:175-84. [DOI: 10.1007/s12072-015-9673-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
97 Fukubayashi K, Tanaka M, Izumi K, Watanabe T, Fujie S, Kawasaki T, Yoshimaru Y, Tateyama M, Setoyama H, Naoe H. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method. Cancer Med. 2015;4:1214-1223. [PMID: 26044168 DOI: 10.1002/cam4.476] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
98 Damdinsuren B, Nagano H, Wada H, Noda T, Natsag J, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Doki Y, Dono K, Monden M. Interferon alpha receptors are important for antiproliferative effect of interferon-alpha against human hepatocellular carcinoma cells. Hepatol Res 2007;37:77-83. [PMID: 17300701 DOI: 10.1111/j.1872-034X.2007.00007.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
99 Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, Nagaoki Y, Kawaoka T, Takaki S, Waki K. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J Gastroenterol Hepatol. 2012;27:1850-1857. [PMID: 23020312 DOI: 10.1111/j.1440-1746.2012.07276.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
100 Tian Z, Si J, Chang Q, Zhou L, Chen S, Xiao P, Wu E. Antitumor activity and mechanisms of action of total glycosides from aerial part of Cimicifuga dahurica targeted against hepatoma. BMC Cancer 2007;7:237. [PMID: 18166137 DOI: 10.1186/1471-2407-7-237] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
101 Katamura Y, Aikata H, Kimura Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Ishikawa M, Hieda M, Kakizawa H, Chayama K. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases: Chemotherapy for hepatoma. Journal of Gastroenterology and Hepatology 2010;25:1117-22. [DOI: 10.1111/j.1440-1746.2009.06110.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
102 Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H, Kobayashi S, Marubashi S, Takeda Y, Dono K. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer. 2009;100:1647-1658. [PMID: 19401692 DOI: 10.1038/sj.bjc.6605064] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 6.5] [Reference Citation Analysis]
103 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 6.5] [Reference Citation Analysis]
104 Okada Y, Wang T, Kasai K, Suzuki K, Takikawa Y. Regulation of transforming growth factor is involved in the efficacy of combined 5-fluorouracil and interferon alpha-2b therapy of advanced hepatocellular carcinoma. Cell Death Discov 2018;4:42. [PMID: 29560281 DOI: 10.1038/s41420-018-0040-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Nemoto T, Matsuda H, Nosaka T, Saito Y, Ozaki Y, Hayama R, Naito T, Takahashi K, Ofuji K, Ohtani M, Hiramatsu K, Suto H, Nakamoto Y. Comparison of hepatic arterial infusion chemotherapy and sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series. Mol Clin Oncol 2014;2:1028-34. [PMID: 25279193 DOI: 10.3892/mco.2014.371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Nakamura M, Nagano H, Marubashi S, Miyamoto A, Takeda Y, Kobayashi S, Wada H, Noda T, Dono K, Umeshita K, Monden M. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 2008;112:1765-71. [PMID: 18327806 DOI: 10.1002/cncr.23356] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
107 Chuma M, Taguchi H, Yamamoto Y, Shimizu S, Nakanishi M, Ogawa K, Sho T, Horimoto H, Kobayashi T, Nakai M. Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. J Gastroenterol Hepatol. 2011;26:1123-1132. [PMID: 21501224 DOI: 10.1111/j.1440-1746.2011.06745.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
108 Yashima Y, Sato S, Kawai T, Sugimoto T, Sato T, Kanda M, Obi S. Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma. Hepatol Int 2015;9:142-8. [PMID: 25788388 DOI: 10.1007/s12072-014-9583-z] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
109 Hatano E, Uemoto S, Yamaue H, Yamamoto M; the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap. J Hepatobiliary Pancreat Sci 2018;25:395-402. [DOI: 10.1002/jhbp.574] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
110 Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-α for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scandinavian Journal of Gastroenterology 2009;44:1477-86. [DOI: 10.3109/00365520903367262] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
111 Kooby DA, Egnatashvili V, Graiser M, Delman KA, Kauh J, Wood WC, Staley Iii CA. Changing management and outcome of hepatocellular carcinoma: Evaluation of 501 patients treated at a single comprehensive center: Liver Cancer. J Surg Oncol 2008;98:81-8. [DOI: 10.1002/jso.21049] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
112 Terashima T, Yamashita T, Arai K, Sunagozaka H, Kitahara M, Nakagawa H, Kagaya T, Mizukoshi E, Honda M, Kaneko S. Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. Hepatol Res 2014;44:1179-85. [PMID: 24171787 DOI: 10.1111/hepr.12266] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
113 Fushiya N, Takagi I, Nishino H, Akizuki S, Ohnishi A. Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. Anticancer Drugs 2013;24:617-22. [PMID: 23571497 DOI: 10.1097/CAD.0b013e3283614fef] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
114 Matono R, Yoshiya S, Motomura T, Toshima T, Kayashima H, Masuda T, Yoshizumi T, Taketomi A, Shirabe K, Maehara Y. Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection. HPB (Oxford). 2012;14:247-253. [PMID: 22404263 DOI: 10.1111/j.1477-2574.2011.00436.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
115 Uyama H, Nagano H, Nakamura H, Murakami T, Nakamura H, Monden M, Hayashi N. New chemotherapy for patients with advanced hepatocellular carcinoma: Pilot study of β-interferon and doxorubicin one-shot intra-arterial chemotherapy. Hepatology Research 2007;37:1018-25. [DOI: 10.1111/j.1872-034x.2007.00158.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
116 Nakamura M, Nagano H, Wada H, Noda T, Ota H, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Monden M. A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha. J Gastroenterol 2006;41:1120-5. [PMID: 17160524 DOI: 10.1007/s00535-006-1907-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
117 Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S, Nakajima A, Saito S. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol 2012; 18(16): 1933-1939 [PMID: 22563174 DOI: 10.3748/wjg.v18.i16.1933] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
118 Sakabe T, Tsuchiya H, Kanki K, Azumi J, Gonda K, Mizuta Y, Yamada D, Wada H, Shomori K, Nagano H, Shiota G. Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance. PLoS One 2013;8:e56197. [PMID: 23457527 DOI: 10.1371/journal.pone.0056197] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
119 Kim SH, Oh JS, Chun HJ, Choi BG, Lee HG. Dual-Port versus Mono-Port Implantation for Intra-Arterial Chemoinfusion Therapy for Treatment of Hepatocellular Carcinoma in Patients with Anatomic Hepatic Artery Variation. J Vasc Interv Radiol. 2019;30:23-30. [PMID: 30297310 DOI: 10.1016/j.jvir.2018.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
120 Kondo M, Morimoto M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Aikata H, Hatanaka T, Takizawa D, Matsunaga K, Okuse C, Suzuki M, Taguri M, Ishibashi T, Numata K, Maeda S, Tanaka K. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer 2019;19:954. [PMID: 31615466 DOI: 10.1186/s12885-019-6198-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
121 Tomiyama Y, Yoshioka N, Yanai Y, Kawase T, Nishina S, Hara Y, Yoshida K, Korenaga K, Korenaga M, Hino K. Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma. Hepat Med 2011;3:45-52. [PMID: 24367220 DOI: 10.2147/HMER.S19695] [Reference Citation Analysis]
122 Kawaoka T, Aikata H, Takaki S, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Kamada K, Kitamoto M. Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems. Hepatol Res. 2010;40:1082-1091. [PMID: 20880059 DOI: 10.1111/j.1872-034x.2010.00714.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
123 Kodama H, Aikata H, Murakami E, Miyaki D, Nagaoki Y, Hashimoto Y, Azakami T, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Ishikawa M, Kakizawa H, Awai K, Kenjo M, Nagata Y, Chayama K. Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus. Hepatol Res 2011;41:1046-56. [PMID: 22032677 DOI: 10.1111/j.1872-034X.2011.00857.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Obi S, Sato S, Kawai T. Current Status of Hepatic Arterial Infusion Chemotherapy. Liver Cancer. 2015;4:188-199. [PMID: 26674592 DOI: 10.1159/000367746] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
125 Shi DB, Li XX, Zheng HT, Li DW, Cai GX, Peng JJ, Gu WL, Guan ZQ, Xu Y, Cai SJ. Icariin-mediated inhibition of NF-κB activity enhances the in vitro and in vivo antitumour effect of 5-fluorouracil in colorectal cancer. Cell Biochem Biophys 2014;69:523-30. [PMID: 24435883 DOI: 10.1007/s12013-014-9827-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
126 Liu C, Xing W, Si T, Yu H, Guo Z. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. Oncotarget 2017;8:100734-45. [PMID: 29246017 DOI: 10.18632/oncotarget.20140] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
127 Ding H, Liu J, Liu B, Zeng Y, Chen P, Su Y. Long noncoding RNA PVT1 inhibits interferon-α mediated therapy for hepatocellular carcinoma cells by interacting with signal transducer and activator of transcription 1. Biochem Biophys Res Commun 2018;500:973-80. [PMID: 29715456 DOI: 10.1016/j.bbrc.2018.04.219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
128 Kodama K, Kawaoka T, Aikata H, Uchikawa S, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Masaki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Chayama K. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. J Gastroenterol Hepatol. 2018;33:1780-1786. [PMID: 29645345 DOI: 10.1111/jgh.14152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
129 Hirooka M, Koizumi Y, Kisaka Y, Abe M, Murakami H, Matsuura B, Hiasa Y, Onji M. Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus. AJR Am J Roentgenol. 2010;194:W221-W226. [PMID: 20093578 DOI: 10.2214/ajr.09.2852] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
130 Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. Int J Clin Oncol. 2011;16:221-229. [PMID: 21132451 DOI: 10.1007/s10147-010-0151-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
131 Kawai T, Yashima Y, Sugimoto T, Sato T, Kanda M, Enomoto N, Sato S, Obi S. Emergency endoscopic variceal ligation following variceal rupture in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis: a retrospective study. World J Surg Oncol 2016;14:52. [PMID: 26911980 DOI: 10.1186/s12957-016-0802-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
132 Ueda H, Fukuchi H, Tanaka C. Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review). Oncol Lett. 2012;3:259-263. [PMID: 22740891 DOI: 10.3892/ol.2011.469] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
133 Kim YG, Eun JR, Kim TN, Lee HJ, Kim JW, Chang JC, Yun SS, Choi JH. Pathological complete remission of advanced hepatocellular carcinoma with main portal vein tumor thrombosis by hepatic arterial infusion chemotherapy. Gut Liver 2010;4:266-9. [PMID: 20559534 DOI: 10.5009/gnl.2010.4.2.266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
134 Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Takahashi S. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. Hepatol Res. 2012;42:442-453. [PMID: 22176468 DOI: 10.1111/j.1872-034x.2011.00943.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
135 Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, Aino H, Nakano M, Kawaguchi A, Kakuma T, Sata M. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol 2012;47:686-95. [DOI: 10.1007/s00535-012-0555-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
136 Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006; 12(47): 7561-7567 [PMID: 17171782 DOI: 10.3748/wjg.v12.i47.7561] [Cited by in CrossRef: 185] [Cited by in F6Publishing: 185] [Article Influence: 11.6] [Reference Citation Analysis]
137 Pinto LC, Soares BM, Pinheiro Jde J, Riggins GJ, Assumpção PP, Burbano RM, Montenegro RC. The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model. Toxicol In Vitro 2015;29:2038-44. [PMID: 26315676 DOI: 10.1016/j.tiv.2015.08.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
138 Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-685. [PMID: 20633193 DOI: 10.1111/j.1872-034x.2010.00673.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 47] [Article Influence: 11.7] [Reference Citation Analysis]
139 Yamashita T, Kaneko S. Treatment strategies for hepatocellular carcinoma in Japan. Hepatol Res. 2013;43:44-50. [PMID: 22583802 DOI: 10.1111/j.1872-034x.2012.01029.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
140 Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-chayama H, Kawakami Y, Ochi H, Chayama K. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. J Gastroenterol 2018;53:107-18. [DOI: 10.1007/s00535-017-1348-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
141 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019; 25(31): 4360-4382 [PMID: 31496618 DOI: 10.3748/wjg.v25.i31.4360] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 20] [Article Influence: 9.7] [Reference Citation Analysis]
142 Tanaka K, Yabushita Y, Nakagawa K, Kumamoto T, Matsuo K, Taguri M, Endo I. Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: A pilot study. European Journal of Surgical Oncology (EJSO) 2013;39:1364-70. [DOI: 10.1016/j.ejso.2013.10.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
143 Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, Choi YM, Han SY. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol 2012; 18(26): 3426-3434 [PMID: 22807613 DOI: 10.3748/wjg.v18.i26.3426] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
144 Moriguchi M, Furuta M, Itoh Y. A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus. J Clin Transl Hepatol 2017;5:177-83. [PMID: 28660156 DOI: 10.14218/JCTH.2016.00075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
145 Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S, Takeda Y, Dono K, Umeshita K, Sakon M, Monden M. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer. 2007;110:2493-2501. [PMID: 17941012 DOI: 10.1002/cncr.23033] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
146 Miyaki D, Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Yoshimatsu R, Yamagami T, Awai K, Chayama K. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers. J Gastroenterol Hepatol 2015;30:726-32. [PMID: 25311578 DOI: 10.1111/jgh.12821] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
147 Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2010;6:80-8. [PMID: 20565419 DOI: 10.1111/j.1743-7563.2010.01287.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
148 Tateishi R, Shiina S, Akahane M, Sato J, Kondo Y, Masuzaki R, Nakagawa H, Asaoka Y, Goto T, Otomo K, Omata M, Yoshida H, Koike K. Frequency, risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma. PLoS One 2013;8:e59040. [PMID: 23593129 DOI: 10.1371/journal.pone.0059040] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
149 Kim B, Won JH, Kim J, Kwon Y, Cho HJ, Huh J, Kim JK. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival. AJR Am J Roentgenol 2021;216:1566-73. [PMID: 33852336 DOI: 10.2214/AJR.20.23213] [Reference Citation Analysis]
150 Uka K, Aikata H, Takaki S, Kawaoka T, Saneto H, Miki D, Takahashi S, Toyota N, Ito K, Chayama K. Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases. World J Gastroenterol 2008; 14(16): 2602-2608 [PMID: 18442216 DOI: 10.3748/wjg.14.2602] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
151 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 7.3] [Reference Citation Analysis]
152 Kim SL, Kim SH, Trang KT, Kim IH, Lee SO, Lee ST, Kim DG, Kang SB, Kim SW. Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. Cancer Lett 2013;335:479-86. [PMID: 23507557 DOI: 10.1016/j.canlet.2013.03.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
153 Walcott-Sapp S, Naugler S, Lim JY, Wagner J, Orloff SL, Farsad K, Kolbeck KJ, Kaufman J, Maynard E, Enestvedt CK, Mayo SC, Billingsley KG. Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center. J Gastrointest Oncol 2018;9:1074-83. [PMID: 30603126 DOI: 10.21037/jgo.2018.08.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
154 Kosaka Y, Kimura T, Kawaoka T, Ogawa Y, Amioka K, Naruto K, Yoshikawa Y, Kikukawa C, Suehiro Y, Yamaoka K, Ando Y, Uchikawa S, Morio K, Nakahara T, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chosa K, Awai K, Nagata Y, Chayama K, Aikata H. Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. Liver Cancer 2021;10:151-60. [PMID: 33977091 DOI: 10.1159/000513706] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
155 Ma MC, Chen YY, Li SH, Cheng YF, Wang CC, Chiu TJ, Pei SN, Liu CT, Huang TL, Huang CH, Su YL, Chen YH, Lu SN, Rau KM. Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. ScientificWorldJournal 2014;2014:160138. [PMID: 24967421 DOI: 10.1155/2014/160138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
156 Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol. 2012;47:1152-1159. [PMID: 22438097 DOI: 10.1007/s00535-012-0574-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
157 Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki KI, Ohta H, Yoshida T, Kamimura T. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: A pilot study. World J Gastroenterol 2007; 13(41): 5465-5470 [PMID: 17907289 DOI: 10.3748/wjg.v13.i41.5465] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
158 Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, Mizukoshi E, Sakai A, Nakamoto Y, Honda M. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology. 2011;81:281-290. [PMID: 22133996 DOI: 10.1159/000334439] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
159 Koga Y, Beppu T, Imai K, Kuramoto K, Miyata T, Kitano Y, Nakagawa S, Okabe H, Okabe K, Yamashita YI, Chikamoto A, Baba H. Complete remission of advanced hepatocellular carcinoma following transient chemoembolization and portal vein ligation. Surg Case Rep 2018;4:102. [PMID: 30159613 DOI: 10.1186/s40792-018-0510-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
160 Kondo M, Morimoto M, Numata K, Nozaki A, Tanaka K. Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Jpn J Clin Oncol. 2011;41:69-75. [PMID: 20688778 DOI: 10.1093/jjco/hyq145] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
161 Shirasaki T, Honda M, Yamashita T, Nio K, Shimakami T, Shimizu R, Nakasyo S, Murai K, Shirasaki N, Okada H, Sakai Y, Sato T, Suzuki T, Yoshioka K, Kaneko S. The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication. Sci Rep 2018;8:13143. [PMID: 30177680 DOI: 10.1038/s41598-018-31421-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
162 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms20061358] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 19.7] [Reference Citation Analysis]
163 Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Chayama K. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib: Sorafenib for HCC with extrahepatic metastasis. Hepatol Res 2014;44:1320-8. [DOI: 10.1111/hepr.12307] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
164 Tao ZW, Cheng BQ, Zhou T, Gao YJ. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00229-0. [PMID: 34955380 DOI: 10.1016/j.hbpd.2021.12.004] [Reference Citation Analysis]
165 Ikeda M, Okusaka T, Sato Y, Furuse J, Mitsunaga S, Ueno H, Morizane C, Inaba Y, Kobayashi T, Arai Y. A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. Japanese Journal of Clinical Oncology 2017;47:512-9. [DOI: 10.1093/jjco/hyx038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
166 Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol 2015; 21(36): 10314-10326 [PMID: 26420958 DOI: 10.3748/wjg.v21.i36.10314] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
167 Hatooka M, Kawaoka T, Aikata H, Inagaki Y, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Awai K, Masaki K, Waki K, Kohno H, Kohno H, Moriya T, Nagaoki Y, Tamura T, Amano H, Katamura Y, Chayama K. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC Cancer 2018;18:633. [PMID: 29866075 DOI: 10.1186/s12885-018-4519-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
168 Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Manousou P, Arvaniti V, Burroughs AK. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;2:761-84. [DOI: 10.1586/17474124.2.6.761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
169 Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. p53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene. 2011;30:2670-2678. [PMID: 21399658 DOI: 10.1038/onc.2010.635] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
170 Zaitsu J, Yamasaki T, Saeki I, Harima Y, Iwamoto T, Harima Y, Matsumoto T, Urata Y, Hidaka I, Marumoto Y. Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. Hepatol Res. 2014;44:481-490. [PMID: 23607437 DOI: 10.1111/hepr.12141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
171 Fujino H, Kimura T, Aikata H, Miyaki D, Kawaoka T, Kan H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Takahashi S, Yoshimatsu R, Yamagami T, Kenjo M, Nagata Y, Awai K, Chayama K. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2015;45:607-617. [PMID: 25052365 DOI: 10.1111/hepr.12392] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
172 Katamura Y, Aikata H, Kimura Y, Azakami T, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Chayama K. Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-α in a hemodialysis patient. Hepatology Research 2009;39:415-20. [DOI: 10.1111/j.1872-034x.2008.00448.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
173 Taguchi M, Sakuma Y, Sasanuma H, Sata N, Lefor AK, Sasaki T, Tanaka A, Yasuda Y. Complete pathological response to transcatheter arterial infusion despite a rapidly progressing recurrent hepatocellular carcinoma with portal vein tumor thrombus: A case report. Int J Surg Case Rep 2015;10:20-4. [PMID: 25790913 DOI: 10.1016/j.ijscr.2015.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
174 Subbotin VM. Privileged portal metastasis of hepatocellular carcinoma in light of the coevolution of a visceral portal system and liver in the chordate lineage: a search for therapeutic targets. Drug Discov Today 2018;23:548-64. [PMID: 29330122 DOI: 10.1016/j.drudis.2018.01.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
175 Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:424-432. [PMID: 29631810 DOI: 10.1016/s2468-1253(18)30078-5] [Cited by in Crossref: 75] [Cited by in F6Publishing: 52] [Article Influence: 18.8] [Reference Citation Analysis]
176 Moriguchi M, Umemura A, Itoh Y. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. Clin J Gastroenterol 2016;9:184-90. [PMID: 27401471 DOI: 10.1007/s12328-016-0670-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
177 Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117:4475-4483. [PMID: 21437884 DOI: 10.1002/cncr.25960] [Cited by in Crossref: 228] [Cited by in F6Publishing: 209] [Article Influence: 20.7] [Reference Citation Analysis]
178 Kawaoka T, Aikata H, Kobayashi T, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Inagaki Y, Honda F, Hatooka M, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Baba Y, Awai K, Chayama K. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. Hepatol Res 2018;48:1118-30. [PMID: 30030881 DOI: 10.1111/hepr.13232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
179 Takatori H, Yamashita T, Honda M, Nishino R, Arai K, Yamashita T, Takamura H, Ohta T, Zen Y, Kaneko S. dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma. Liver Int 2010;30:438-46. [PMID: 19968781 DOI: 10.1111/j.1478-3231.2009.02177.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
180 Kang J, Nie Q, DU R, Zhang L, Zhang J, Li Q, Li J, Qi W. Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Mol Clin Oncol. 2014;2:43-50. [PMID: 24649306 DOI: 10.3892/mco.2013.196] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
181 Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2015;4:253-262. [PMID: 26734579 DOI: 10.1159/000367743] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 10.4] [Reference Citation Analysis]
182 Kobayashi T, Suzuki H, Kubo N, Watanabe A, Sasaki S, Wada W, Araki K, Shimura T, Kuwano H. A case of hepatocellular carcinoma with portal vein tumor thrombosis successfully treated by a combination of intra-arterial infusion 5-fluorouracil, cisplatin, and systemic interferon-α therapies. Int Surg 2012;97:230-4. [PMID: 23113851 DOI: 10.9738/CC24.1] [Reference Citation Analysis]
183 Zhao L, Sha Y, Zhao Q, Yao J, Zhu B, Lu Z, You Q, Guo Q. Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway. Biochem Cell Biol 2013;91:221-9. [DOI: 10.1139/bcb-2012-0077] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
184 Onishi H, Nouso K, Nakamura S, Katsui K, Wada N, Morimoto Y, Miyahara K, Takeuchi Y, Kuwaki K, Yasunaka T. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. Hepatol Int. 2015;9:105-112. [PMID: 25788384 DOI: 10.1007/s12072-014-9592-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
185 Kishi Y, Hasegawa K, Sugawara Y, Kokudo N. Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol. 2011;2011:728103. [PMID: 21994868 DOI: 10.4061/2011/728103] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]